Home » Partner With Us » For Researchers & Clinicians
SARC was formed in 2003 by a core group of sarcoma experts who recognized the value of bringing together the best cancer centers and researchers in the world. It is one of the few organizations that focuses on all types of sarcoma.
The sarcoma research, clinical, and patient communities are geographically scattered and under-resourced. It is essential to share scientific knowledge and advance research for improved treatments to defeat sarcoma.
Simply put, SARC drives high-impact, centrally-supported collaboration among the sarcoma research community.
Funding Opportunities » Publications » SARC Clinical Trials » Join the Tumor Board » Use SARC Resources » Add your center to the Directory » About the SARC Consortium »
Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials.
SARC can help you. We’re committed to helping bring together sarcoma specialists dedicated to laboratory research and clinical studies.
RESOURCES
The SARC Biospecimen Bank is designed to help qualified sarcoma investigators or organizations gain access to de-identified specimens to carry out projects that may explore relevant biomarkers, identify novel therapeutic targets, or make other translational discoveries. SARC invites applications to conduct translational research using these materials.
Learn more about the SARC Biospecimen Bank.
SARC has established a repository of clinical data sets from 12 clinical trials, including more than 1,700 patients.
Learn more about the SARC Clinical Data Repository.
SARC imaging data collected from two clinical trials is now available to sarcoma researchers for further query.
Learn more about SARC Imaging Resources.
We foster collaboration among investigators, academia, and pharma. The National Cancer Institute (NCI) agent formulary (NCI Formulary) is a public-private partnership between the NCI and pharmaceutical and biotechnology companies with a purpose of providing academic investigators with rapid access to agents or combinations of agents for cancer clinical trial use. Agents within the NCI Formulary are available to investigators at NCI-designated Cancer Centers for the conduct of clinical trials under investigator-held IND, as well as pre-clinical research.
Visit the NCI Formulary website to review the list of available agents.
The National Cancer Institute performed a screen of 100 FDA-approved compounds and 345 investigational agents in 63 adult and pediatric sarcoma cell lines. Gene expression and miRNA expression is also available.
See results published at NIH National Center for Biotechnology Information.